8-K: DBV Technologies Secures FDA Agreement, Accelerating Viaskin Peanut Patch BLA Submission Timeline

DBV Technologies announces an agreement with the FDA regarding safety exposure data for its Viaskin Peanut patch, potentially accelerating the BLA submission timeline to the first half of 2026, and reports unaudited 2024 financial results.

Summary

• DBV Technologies announced that the FDA agreed that safety exposure data from the VITESSE Phase 3 study is sufficient to support a BLA filing for the Viaskin peanut patch in children aged 4-7 years.
• The COMFORT Children supplemental safety study is no longer required, accelerating the BLA submission timeline.
• The company now expects to submit the BLA in the first half of 2026, potentially accelerating the product launch by approximately one year, subject to FDA approval.
• Topline results from the VITESSE Phase 3 study are expected in the fourth quarter of 2025.
• DBV also plans to pursue an Accelerated Approval pathway for the Viaskin peanut patch in toddlers aged 1-3 years, with the COMFORT Toddlers study expected to initiate in the second quarter of 2025 and BLA submission expected in the second half of 2026.
• Unaudited financial results for 2024 show cash and cash equivalents of $32.5 million as of December 31, 2024, compared to $141.4 million as of December 31, 2023.
• The company's available cash and cash equivalents are expected to fund operations only into April 2025, raising substantial doubt about its ability to continue as a going concern.
• The company intends to seek additional capital to continue research and development efforts and prepare for the BLA filing and launch of Viaskin Peanut patch.
• Operating income for 2024 was $4.2 million, compared to $15.7 million in 2023.
• Operating expenses for 2024 were $120.7 million, compared to $92.2 million in 2023.
• The company recorded a net loss of $113.9 million for 2024, compared to a net loss of $72.7 million for 2023.
• Net loss per share was $(1.17) for 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the FDA agreement and potential acceleration of the BLA submission. However, concerns about the company's cash runway and significant net loss temper the overall outlook.

Positives

• FDA agreement on safety exposure data accelerates the BLA submission timeline for the Viaskin peanut patch in children aged 4-7 years.
• The potential product launch could be accelerated by approximately one year, subject to FDA approval.
• The VITESSE Phase 3 study enrolled 654 participants, making it the largest Phase 3 clinical trial for peanut allergy ever conducted in this age group.
• DBV plans to pursue an Accelerated Approval pathway for the Viaskin peanut patch in toddlers aged 1-3 years.

Negatives

• The company's available cash and cash equivalents are expected to fund operations only into April 2025, raising substantial doubt about its ability to continue as a going concern.
• The company recorded a net loss of $113.9 million for the year ended December 31, 2024, a significant increase from the net loss of $72.7 million for the year ended December 31, 2023.
• Operating income decreased by $11.5 million compared to the same period in 2023.

Risks

• The company's ability to obtain necessary financing to continue operations is uncertain.
• The company may have to scale back its operations if it is not successful in its financing objectives.
• There are uncertainties associated with research and development, clinical trials, and regulatory reviews and approvals.
• The review of potential financial and strategic options may not result in any particular action or transaction being pursued.
• If the Company is unable to continue as a going concern, it may have to liquidate its assets and investors may lose all or part of their investment.

Future Outlook

DBV Technologies anticipates submitting a BLA for the Viaskin peanut patch in children aged 4-7 years in the first half of 2026 and plans to pursue an Accelerated Approval pathway for toddlers aged 1-3 years, with a BLA submission expected in the second half of 2026. The company needs to raise additional funds to finance its activities and is actively reviewing potential financing and strategic options.

Management Comments

• Daniel Tass, Chief Executive Officer, stated that the FDA alignment represents a tremendous achievement for food allergy families, clinicians, researchers, and external partners.
• Daniel Tass thanked the FDA for their collaboration and constructive approach.
• Dr. David Fleischer, Global Principal Investigator, VITESSE, expressed pleasure that the FDA agrees that the VITESSE safety exposure data is sufficiently robust to support a BLA.
• Dr. James Tracy, President, American College of Allergy, Asthma, and Immunology (ACAAI), expressed support for potential new innovations in food allergy, including the Viaskin peanut patch.

Industry Context

This announcement is relevant to the broader food allergy treatment landscape, where there is a significant unmet need for safe and effective therapies. DBV Technologies' progress with the Viaskin peanut patch could provide a new treatment option for children with peanut allergies, potentially competing with existing and emerging therapies.

Comparison to Industry Standards

• Aimmune Therapeutics' Palforzia is an existing FDA-approved oral immunotherapy for peanut allergy, requiring a strict dosing schedule and medical supervision.
• DBV's Viaskin patch offers an alternative approach through epicutaneous immunotherapy, potentially providing a safer and more convenient option.
• Other companies like Alladapt Immunotherapeutics are also developing oral immunotherapies for food allergies, indicating a competitive landscape.
• The VITESSE trial, with 654 participants, is one of the largest peanut allergy trials, suggesting a robust dataset for regulatory review.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial situation and need for additional capital.
• Employees may be affected by potential scaling back of operations if financing is not secured.
• Patients with peanut allergies could benefit from the potential approval of the Viaskin peanut patch.
• Clinicians may have a new treatment option for peanut allergies.

Next Steps

• DBV will commence preparations for a BLA submission in the first half of 2026.
• DBV will continue the VITESSE Phase 3 study, with topline results expected in the fourth quarter of 2025.
• DBV plans to initiate the COMFORT Toddlers 6-month supplemental safety study in the second quarter of 2025.
• DBV will continue to seek additional capital to finance its activities.

Key Dates

Keywords

Viaskin Peanut patch, DBV Technologies, FDA, BLA, Peanut allergy, VITESSE, COMFORT, Clinical trial, Financial results, Cash runway, Biopharmaceutical